Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Clermont Oncology Center ( Site 0041), Clermont, Florida Israel
Shaare Zedek Medical Center ( Site 0186), Jerusalem Sheba Medical Center ( Site 0180), Ramat Gan South Korea
Severance Hospital, Yonsei University Health System ( Site 0080), Seoul